A Study to Evaluate the Effect of Co-administration on the Pharmacokinetics of SPR720, Azithromycin, and Ethambutol in Healthy Participants
Study Details
Study Description
Brief Summary
The primary purpose of this study is to evaluate the pharmacokinetics (PK) of SPR720, azithromycin, and ethambutol, administered separately and co-administered, in healthy adult participants.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: SPR720 1000 mg Healthy participants will receive SPR720 1000 milligrams (mg), orally, once daily (QD) for 7 days. |
Drug: SPR720
Multiple oral doses of SPR720 capsules.
|
| Experimental: Azithromycin 500 mg Healthy participants will receive azithromycin 500 mg, orally, QD for 7 days. |
Drug: Azithromycin
Multiple oral doses of azithromycin.
|
| Experimental: Ethambutol 800 mg Healthy participants will receive ethambutol 800 mg, orally, QD for 7 days. |
Drug: Ethambutol
Multiple oral doses of ethambutol.
|
| Experimental: SPR720 1000 mg + Azithromycin 500 mg + Ethambutol 800 mg Healthy participants will be co-administered SPR720 1000 mg, azithromycin 500 mg, and ethambutol 800 mg, orally, QD for 7 days. |
Drug: SPR720
Multiple oral doses of SPR720 capsules.
Drug: Azithromycin
Multiple oral doses of azithromycin.
Drug: Ethambutol
Multiple oral doses of ethambutol.
|
Outcome Measures
Primary Outcome Measures
- Maximum Observed Plasma Concentration (Cmax) of Study Drug [Pre-dose and at multiple time points post-dose up to Day 8]
- Time to Attain Maximum Plasma Concentration (tmax) for Study Drug [Pre-dose and at multiple time points post-dose up to Day 8]
- Area Under the Concentration-time Curve From Time Zero to Dosing Interval (AUC0-τ) for Study Drug [Pre-dose and at multiple time points post-dose up to Day 8]
Secondary Outcome Measures
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) [From the first dose of study drug through follow-up Day 13]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Body mass index (BMI) between ≥18.0 and ≤32.0 kilograms per meter square (kg/m^2) and weight between 50.0 and 100.0 kilograms (kg) (inclusive) at the Screening visit.
-
Medically healthy without clinically significant medical history, abnormalities in physical examination, laboratory tests, vital signs, or electrocardiogram (ECG) at the Screening visit.
-
Has suitable venous access for repeated blood sampling.
-
Has ability and willingness to abstain from alcohol, caffeine, xanthine-containing beverages or food (coffee, tea, chocolate, and caffeine-containing sodas, colas, etc.) or products containing any of these from 48 hours prior to study drug administration until discharge from the clinical research unit (CRU).
Exclusion Criteria:
-
Has a history of clinically significant acute illness or surgery within the previous 3 months prior to Screening Visit or Day -1.
-
Has a known history of clinically significant hypersensitivity reaction or anaphylaxis to any medication.
-
Has any condition possibly affecting drug absorption (e.g., previous surgery on the gastrointestinal tract [including removal of parts of the stomach, bowel, liver, gall bladder, or pancreas]). History of uncomplicated appendectomy ≥1 year prior to Screening Visit would not be considered exclusionary at the discretion of the Investigator.
-
Is unable to swallow the dosage forms.
-
Has received any other investigational medicinal product or participation in another investigational clinical study that included drug treatment within 30 days prior to Day 1 dose (based on the timing of the last Follow-up Visit for the previous study to Day 1 of the current study).
[Note: Other inclusion and exclusion criteria as per protocol may apply.]
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Spero Therapeutics
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SPR720-102